5-star Wellness Resort
5-star Wellness Resort
Written by: Chris Butt, Certified Personal Trainer & Weight Loss Coach, Premier Fitness Camp
Menopause reshapes your metabolism, appetite, and body composition in ways that make weight loss feel frustrating. This guide explains how GLP-1 medications fit into that picture, how to protect your muscle and bone, and how Premier Fitness Camp helps you turn short-term results into lasting change.
Declining estrogen triggers a cascade of metabolic changes. Fat storage shifts from the hips and thighs to the abdomen, insulin resistance increases, and hunger-regulating hormones ghrelin and leptin become dysregulated. Hormonal shifts alone reduce basal metabolism by 250–300 calories daily. The resulting visceral “menopause belly” fat is metabolically dangerous, linked to elevated cardiovascular risk, insulin resistance, and systemic inflammation. It is far more than an aesthetic concern.
Dr. Mary Claire Haver, a leading menopause expert, has stated: “I was trained in the traditional calories-in, calories-out model and initially viewed menopause weight gain as a behavioral failure.” She has changed her view based on the evidence, and women deserve the same shift in perspective.
GLP-1 receptor agonists mimic a natural gut hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity. Estrogen decline suppresses the body’s own GLP-1 production, so these medications directly address a core metabolic disruption of menopause. A post hoc analysis of the pooled STEP trials presented at Obesity Week 2025 found clinically meaningful weight loss across premenopausal, perimenopausal, and postmenopausal women, with postmenopausal women achieving a median 14 cm waist circumference reduction on subcutaneous semaglutide. The SURMOUNT post hoc analysis found tirzepatide produced approximately 23% total body weight loss in both perimenopausal and postmenopausal women, with 97–98% achieving at least 5% weight loss.
GLP-1s do not treat hot flashes or night sweats. They do not act on the KNDy neuron pathway that drives vasomotor symptoms. Even so, weight-related quality-of-life improvements such as reduced urinary incontinence, less osteoarthritis pain, and better physical function appear across menopause stages.
The evidence base for selecting a GLP-1 for menopause weight loss has grown substantially in 2025–2026. The table below summarizes the key head-to-head data. It draws on the SURMOUNT-5 trial published in the New England Journal of Medicine (2025) and the 2026 Clinical Obesity meta-analysis.
| Factor | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| Average weight loss (SURMOUNT-5, 72 weeks) | 20.2% | 13.7% |
| Lean mass proportion of weight lost | ~25% | Up to 40% |
| GI-related discontinuation rate (SURMOUNT-5) | 2.7% | 5.6% |
| Monthly list price (2026) | ~$1,086 | ~$1,349 |
The lean mass difference is clinically significant for menopausal women, who already lose 1–2% of muscle annually. In FDA approval trials, nausea was reported by 44% of Wegovy users versus 25–29% of Zepbound users. Side-effect profiles and tolerability therefore matter as much as headline weight-loss numbers.
Newer options are expanding the field. The FDA approved oral orforglipron (Foundayo) in April 2026, and post hoc analyses showed postmenopausal women lost up to 28.2 lbs (14.1%) at 72 weeks on the highest dose in the ATTAIN-1 trial. In March 2026, the FDA approved Wegovy HD (semaglutide 7.2 mg), which demonstrated an average 20.7% weight loss.
Individual responses vary. As Dr. Daniel Ghiyam notes: “I have had patients achieve amazing results on semaglutide who didn’t respond very well to tirzepatide, and vice versa.” The right choice depends on medical history, side-effect tolerance, cost, and insurance coverage, and a physician must guide that decision.
For many menopausal women, the most powerful approach involves more than a single medication. Combining a GLP-1 with hormone therapy can amplify results when used appropriately.
Recent studies suggest that pairing menopausal hormone therapy (MHT or HRT) with GLP-1 medications produces greater weight loss than either approach alone. A 2024 study in the Menopause journal (Hurtado et al., n=106 postmenopausal women) found that those on semaglutide plus HRT lost 16% of body weight at 12 months versus 12% on semaglutide alone, with the HRT advantage statistically significant at every timepoint.
Lead author Dr. Regina Castaneda stated: “These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness.” Senior author Dr. Maria Daniela Hurtado Andrade added the important caveat: “Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss.”
The biological rationale supports this combination. Estrogen therapy can attenuate visceral fat gain by as much as 60%, and HRT improves sleep quality and energy levels, which makes consistent exercise more realistic. When discussing this combination with a healthcare provider, relevant questions include:
GLP-1 therapy for menopausal women carries risks that extend beyond the number on the scale. A 2024 phase 2 trial by Hansen et al. (eClinicalMedicine) found that 52 weeks of semaglutide reduced total hip bone mineral density by 2.6% and lumbar spine density by 2.1%, with bone resorption outpacing formation. Dr. Jeremy Burnham describes postmenopausal women as facing a “compounded vulnerability,” with estrogen-driven bone loss layered on top of GLP-1-driven bone loss.
The SURMOUNT-1 DXA substudy found tirzepatide reduced lean body mass by 10.9% over 72 weeks. Muscle functions as metabolic currency. Losing it lowers resting metabolic rate, which drives much of the weight regain that occurs after stopping GLP-1s. Experts recommend a protection protocol that includes:
This is precisely where Premier Fitness Camp delivers a measurable advantage. A case study conducted with the University of California, San Diego (UCSD) evaluated Premier Fitness Camp participants who stayed four or more weeks and received DEXA scans at the start and end of their program. The findings showed that 94% of client weight loss was purely fat, compared to the 60/40 fat-to-muscle ratio typical of standard dieting. Most long-term Premier Fitness Camp clients not only maintained their lean muscle stores but increased them.
With 4–5 hours of daily training, a 3–4:1 trainer-to-client ratio, and registered dietitians designing every meal, Premier Fitness Camp provides a structured environment that makes muscle preservation realistic during active weight loss. As client Irene Tchaikovsky shared: “What began as a simple one-week reboot has transformed into a complete lifestyle shift. Premier Fitness Camp equips you with the knowledge, tools, and support to make meaningful and sustainable changes.”
Protecting muscle and bone is only half of the equation. What you eat and how you move every day also shape your results on GLP-1s and beyond.
What you eat can either compound or counteract menopause-related metabolic changes. Sugary beverages, ultra-processed snacks, refined carbohydrates, and excess alcohol promote visceral fat accumulation and worsen insulin resistance. Prioritizing lean proteins, leafy greens, whole grains, and anti-inflammatory foods supports GLP-1 effectiveness and overall metabolic health.
Exercise works alongside nutrition to reshape body composition. A mix of resistance training 2–3 times weekly, cardiovascular work, and flexibility practice produces strong outcomes. Dr. Mary Claire Haver notes that “high cortisol makes the body more likely to store fat and resist fat loss, even with calorie control”, so stress management and adequate sleep function as core parts of any menopause weight loss strategy.
Premier Fitness Camp’s “Think, Eat, Move” philosophy addresses all three dimensions at once. Licensed psychologists lead behavioral health workshops. Registered dietitians and wellness chefs teach sustainable nutrition, including cooking demonstrations clients can replicate at home. Certified trainers deliver structured, progressive fitness programming adapted to every fitness level. Progress is tracked across 17 health data points weekly, from body composition and blood pressure to glucose, cholesterol, strength, and cardiovascular fitness.
Women who want support building these habits can work with the Premier Fitness Camp team. Talk with a GLP-1–savvy coach today, or call (888) 488-8936 to discuss your goals.
The financial reality of GLP-1 therapy remains a significant barrier for many women. Wegovy lists at approximately $1,349 per month and Zepbound at $1,086 per month in 2026. Only 20–25% of commercial insurance plans cover weight loss medications, with most requiring prior authorization and a BMI of 30+ (or 27+ with a comorbidity).
The Medicare GLP-1 Bridge Program, launching July 1, 2026, provides eligible Medicare Part D beneficiaries access to Wegovy, Zepbound, and Foundayo for $50 per month through December 31, 2027. For cash-pay patients, manufacturer programs can reduce costs. LillyDirect offers Zepbound vials from $299–$449 per month, and NovoCare offers Wegovy from $199–$349 per month. Novo Nordisk has announced a Wegovy price cut to $675 per month effective January 1, 2027. The newly approved oral Foundayo carries a list price of up to approximately $350 per month, which may represent a more accessible entry point for some patients.
Over 50% of GLP-1 users stop within one year, and after stopping, participants regain approximately two-thirds of lost weight within a year, primarily as fat, which leaves body composition worse than baseline. Dr. Rocio Salas-Whalen, a triple board-certified endocrinologist, emphasizes: “The maintenance phase is actually the most important part of treatment.”
Building sustainable habits during treatment creates a smoother transition later. Premier Fitness Camp offers a structured answer to this challenge. Located at the Omni La Costa Resort & Spa in Carlsbad, California, Premier Fitness Camp’s all-inclusive program follows the “Think, Eat, Move” philosophy. Clients train 4–5 hours daily with a 3–4:1 trainer-to-client ratio, learn nutrition from registered dietitians and wellness chefs, and receive behavioral health support from licensed psychologists.
The UCSD case study mentioned earlier shows that the right program can preserve and build muscle during active weight loss, which protects the metabolic rate that determines long-term maintenance. With 1,200+ reviews, a 90%+ five-star rating, and 50% of annual revenue from returning alumni, Premier Fitness Camp has helped over 3,000 clients transform their lives. For women on GLP-1s, Premier Fitness Camp provides an “exit ramp,” a structured environment to rebuild muscle, establish sustainable nutrition habits, and transition off medication with confidence.
The evidence shows that GLP-1 medications work for menopause-related weight loss, especially when paired with a plan to protect muscle and bone. The SURMOUNT and STEP data confirm their efficacy across menopause stages, and early research on combining them with hormone therapy looks promising. Medication alone cannot safeguard your muscle, bone density, or long-term results. Protecting lean mass, discussing hormone therapy with your physician, and building sustainable habits determine whether your progress lasts beyond the prescription.
Premier Fitness Camp offers the education, expert guidance, and immersive environment needed to maximize your results and transition off medication with confidence. Plan your personalized GLP-1 strategy with Premier Fitness Camp today. Call (888) 488-8936 or book your consultation online.
GLP-1 receptor agonists do not selectively target abdominal fat, yet they produce meaningful reductions in visceral adiposity as part of overall weight loss. In clinical trials, postmenopausal women on subcutaneous semaglutide achieved a median waist circumference reduction of 14 cm, and menopausal women on tirzepatide reduced waist circumference by approximately 20 cm at 72 weeks. These reductions in central adiposity carry significant metabolic benefits, including improved insulin sensitivity and reduced cardiovascular risk, both of which matter greatly after menopause. Combining GLP-1 therapy with resistance training and adequate protein intake further supports favorable body composition changes and directs more of the weight loss toward fat.
Current observational data suggest the combination appears safe and potentially synergistic. Multiple studies, including a 2024 Menopause journal study and a 2026 Mayo Clinic retrospective published in The Lancet, found that postmenopausal women on both GLP-1 medications and hormone therapy lost significantly more weight than those on GLP-1s alone. The biological rationale includes estrogen’s role in limiting visceral fat accumulation and improving sleep and energy, which supports consistent exercise.
The evidence base still comes from observational research rather than randomized controlled trials. Women should therefore discuss the combination with a physician who can evaluate cardiovascular history, cancer risk factors, and contraindications to hormone therapy. Hormone therapy changes always require medical supervision.
Menopausal women face a compounded vulnerability on GLP-1 therapy. Estrogen decline already accelerates bone resorption and reduces muscle mass at approximately 1–2% per year. GLP-1 medications add to this burden. Semaglutide has been shown to reduce hip bone mineral density by approximately 2.6% and lumbar spine density by 2.1% over 52 weeks, while up to 40% of weight lost on semaglutide may be lean mass. Tirzepatide appears to preserve lean mass somewhat better, with approximately 25% of weight lost as lean mass.
The protective protocol described earlier, including higher protein intake, resistance training 2–3 times weekly, calcium and vitamin D supplementation, and baseline DEXA scanning, is essential for this population. A structured program that integrates these elements from the start of GLP-1 therapy produces substantially better body composition outcomes than medication alone.
No GLP-1 medication has been studied exclusively in menopausal women in a head-to-head randomized trial. The available evidence points to tirzepatide as producing greater average weight loss, approximately 23% in perimenopausal and postmenopausal women in the SURMOUNT post hoc analysis, better lean mass preservation, and lower rates of GI-related discontinuation compared with semaglutide. For women with established cardiovascular disease, semaglutide carries a specific FDA indication for cardiovascular risk reduction based on the SELECT trial, which may make it the preferred choice in that context.
Oral options including Wegovy and the newly approved Foundayo (orforglipron) offer alternatives for women who prefer to avoid injections. The best choice remains individualized and should be made with a physician who considers the full clinical picture.
Premier Fitness Camp does not prescribe or manage GLP-1 medications, which remains the role of a physician. Premier Fitness Camp instead provides the lifestyle infrastructure that makes GLP-1 therapy work long-term and prepares clients for a successful transition off medication. The program’s UCSD case study demonstrated that 94% of client weight loss was purely fat, compared to the 60/40 fat-to-muscle ratio typical of standard dieting, a result achieved through 4–5 hours of daily training with a 3–4:1 trainer-to-client ratio, registered dietitian-designed nutrition, and behavioral health support from licensed psychologists.
For women currently on GLP-1s, Premier Fitness Camp adjusts the program to emphasize resistance training and protein targets. For women preparing to reduce or stop their medication, Premier Fitness Camp provides the habit foundation and “Think, Eat, Move” education that help prevent the typical two-thirds weight regain seen within a year of discontinuation without structured lifestyle support.